Cited 8 times in
Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조덕규 | - |
dc.date.accessioned | 2022-11-24T00:53:08Z | - |
dc.date.available | 2022-11-24T00:53:08Z | - |
dc.date.issued | 2021-01 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191064 | - |
dc.identifier.uri | https://www.ahajournals.org/doi/10.1161/JAHA.120.018366 | - |
dc.description.abstract | Background This study sought to investigate the safety of 3-month dual antiplatelet therapy (DAPT) in patients receiving ultrathin sirolimus-eluting stents with biodegradable polymer (Orsiro). Methods and Results The SMART-CHOICE (Smart Angioplasty Research Team: Comparison Between P2Y12 Antagonist Monotherapy vs Dual Anti- platelet Therapy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents) randomized trial compared 3-month DAPT followed by P2Y12 inhibitor monotherapy with 12-month DAPT in 2993 patients undergoing percutaneous coronary intervention. The present analysis was a prespecified subgroup analysis for patients receiving Orsiro stents. As a post hoc analysis, comparisons between Orsiro and everolimus-eluting stents were also done among patients receiving 3-month DAPT. Of 972 patients receiving Orsiro stents, 481 patients were randomly assigned to 3-month DAPT and 491 to 12-month DAPT. At 12 months, the target vessel failure, defined as a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularization, occurred in 8 patients (1.7%) in the 3-month DAPT group and in 14 patients (2.9%) in the 12-month DAPT group (hazard ratio [HR], 0.58; 95% CI, 0.24-1.39; P=0.22). In whole population who were randomly assigned to receive 3-month DAPT (n=1495), there was no significant difference in the target vessel failure between the Orsiro group and the everolimus-eluting stent group (n=1014) (1.7% versus 1.8%; HR, 0.96; 95% CI, 0.41-2.22; P=0.92). Conclusions In patients receiving Orsiro stents, clinical outcomes at 1 year were similar between the 3-month DAPT followed by P2Y12 inhibitor monotherapy and 12-month DAPT strategies. With 3-month DAPT, there was no significant difference in target vessel failure between Orsiro and everolimus-eluting stents. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02079194. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | JOURNAL OF THE AMERICAN HEART ASSOCIATION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aspirin* / administration & dosage | - |
dc.subject.MESH | Aspirin* / adverse effects | - |
dc.subject.MESH | Biodegradable Plastics / pharmacology* | - |
dc.subject.MESH | Clopidogrel* / administration & dosage | - |
dc.subject.MESH | Clopidogrel* / adverse effects | - |
dc.subject.MESH | Coronary Artery Disease / surgery* | - |
dc.subject.MESH | Coronary Restenosis* / diagnosis | - |
dc.subject.MESH | Coronary Restenosis* / etiology | - |
dc.subject.MESH | Coronary Restenosis* / mortality | - |
dc.subject.MESH | Drug-Eluting Stents / adverse effects* | - |
dc.subject.MESH | Dual Anti-Platelet Therapy / methods | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunosuppressive Agents / pharmacology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Outcome and Process Assessment, Health Care | - |
dc.subject.MESH | Percutaneous Coronary Intervention* / adverse effects | - |
dc.subject.MESH | Percutaneous Coronary Intervention* / instrumentation | - |
dc.subject.MESH | Percutaneous Coronary Intervention* / methods | - |
dc.subject.MESH | Platelet Aggregation Inhibitors / administration & dosage | - |
dc.subject.MESH | Platelet Aggregation Inhibitors / adverse effects | - |
dc.subject.MESH | Purinergic P2Y Receptor Antagonists / administration & dosage | - |
dc.subject.MESH | Purinergic P2Y Receptor Antagonists / adverse effects | - |
dc.subject.MESH | Sirolimus / pharmacology* | - |
dc.title | Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Kyeong Ho Yun | - |
dc.contributor.googleauthor | Seung-Yul Lee | - |
dc.contributor.googleauthor | Byung Ryul Cho | - |
dc.contributor.googleauthor | Woo Jin Jang | - |
dc.contributor.googleauthor | Young Bin Song | - |
dc.contributor.googleauthor | Ju-Hyeon Oh | - |
dc.contributor.googleauthor | Woo Jung Chun | - |
dc.contributor.googleauthor | Yong Hwan Park | - |
dc.contributor.googleauthor | Eul-Soon Im | - |
dc.contributor.googleauthor | Jin-Ok Jeong | - |
dc.contributor.googleauthor | Seok Kyu Oh | - |
dc.contributor.googleauthor | Deok-Kyu Cho | - |
dc.contributor.googleauthor | Jong-Young Lee | - |
dc.contributor.googleauthor | Young-Youp Koh | - |
dc.contributor.googleauthor | Jang-Whan Bae | - |
dc.contributor.googleauthor | Jae Woong Choi | - |
dc.contributor.googleauthor | Wang Soo Lee | - |
dc.contributor.googleauthor | Hyuck Jun Yoon | - |
dc.contributor.googleauthor | Seung Uk Lee | - |
dc.contributor.googleauthor | Jang Hyun Cho | - |
dc.contributor.googleauthor | Woong Gil Choi | - |
dc.contributor.googleauthor | Seung-Woon Rha | - |
dc.contributor.googleauthor | Joo Myung Lee | - |
dc.contributor.googleauthor | Taek Kyu Park | - |
dc.contributor.googleauthor | Jeong Hoon Yang | - |
dc.contributor.googleauthor | Jin-Ho Choi | - |
dc.contributor.googleauthor | Seung-Hyuck Choi | - |
dc.contributor.googleauthor | Sang Hoon Lee | - |
dc.contributor.googleauthor | Hyeon-Cheol Gwon | - |
dc.contributor.googleauthor | Joo-Yong Hahn | - |
dc.identifier.doi | 10.1161/JAHA.120.018366 | - |
dc.contributor.localId | A03813 | - |
dc.relation.journalcode | J01774 | - |
dc.identifier.eissn | 2047-9980 | - |
dc.identifier.pmid | 33345567 | - |
dc.subject.keyword | antiplatelet therapy | - |
dc.subject.keyword | coronary artery disease | - |
dc.subject.keyword | percutaneous coronary intervention | - |
dc.contributor.alternativeName | Cho, Deok Kyu | - |
dc.contributor.affiliatedAuthor | 조덕규 | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | e018366 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol.10(1) : e018366, 2021-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.